pyctx.com | ACN 098 391 961 1 28 AUGUST 2026 APPENDIX 4E – PRELIMINARY FINANCIAL REPORT PERTH, Australia and SAN FRANCISCO, California – 28 August 2026 PYC Therapeutics (ASX: PYC) submits the following Appendix 4E – Preliminary Financial Report for the year ended 30 June...
Appendix 4E
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4e-337
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Notification regarding unquoted securities - PYC
- Investor Webinar
- Change of Director's Interest Notice
- Quarterly Activities/Appendix 4C Cash Flow Report
- PKD - Safety Committee Approves Dose Escalation
Later from PYC Therapeutics
- 2026 Annual Report to Shareholders
- Appendix 4G
- 2026 Corporate Governance Statement
- PKD - Presentation of Clinical Safety Data
- Ceasing to be a substantial holder
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics